Deciding whether to buy ARCT stock requires a comprehensive assessment of your personal risk profile, healthcare sector allocation, and investment time horizon. Because clinical-stage biotechnology companies experience extreme share volatility driven by binary clinical trial results and regulatory decisions, investors should consult licensed financial advisors and review fundamental filings before making portfolio choices.